CNS & Neurological Disorders-Drug Targets
Scope & Guideline
Exploring New Horizons in Neurology and Pharmacology
Introduction
Aims and Scopes
- Pharmacological Research:
The journal emphasizes pharmacological studies on various compounds, including natural products, synthetic drugs, and biologics, aimed at understanding their mechanisms of action in treating neurological disorders. - Neurodegenerative Disorders:
A significant focus is placed on neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS), exploring novel therapeutic targets and treatment paradigms. - Neuroinflammation and Neuroprotection:
Research related to neuroinflammation and neuroprotective strategies is a core area, addressing the role of immune responses and potential therapeutic interventions to mitigate neuroinflammatory damage. - Neuropsychiatric Disorders:
The journal also covers neuropsychiatric conditions, investigating the interplay between neurological and psychiatric symptoms, treatment efficacy, and new pharmacological approaches. - Innovative Drug Delivery Systems:
There is a keen interest in exploring novel drug delivery systems, including nanotechnology and transdermal systems, to enhance the efficacy of treatments for CNS disorders. - Molecular Mechanisms and Biomarkers:
The journal promotes research on molecular mechanisms underlying neurological disorders, including the identification of biomarkers for early diagnosis and monitoring of therapeutic responses.
Trending and Emerging
- Microbiome-Gut-Brain Axis:
Recent studies have highlighted the significance of the microbiome-gut-brain axis in neurological disorders, indicating a growing interest in how gut health influences brain function and disease progression. - Neuroinflammation as a Therapeutic Target:
There is an increasing focus on neuroinflammation and its role in various neurological conditions, with research exploring anti-inflammatory strategies as potential therapeutic approaches. - Nanotechnology in Drug Delivery:
Emerging research on nanotechnology for drug delivery systems is gaining momentum, showcasing innovative methods to enhance the bioavailability and efficacy of treatments for CNS disorders. - Genetic and Epigenetic Research:
Investigations into genetic and epigenetic factors influencing neurological disorders are on the rise, emphasizing personalized medicine and targeted therapeutic interventions. - Artificial Intelligence and Machine Learning:
The integration of artificial intelligence and machine learning in analyzing neurological data is becoming a prominent theme, aiding in diagnosis, treatment planning, and outcome prediction. - Phytochemicals and Natural Products:
There is a renewed interest in the therapeutic potential of phytochemicals and natural products, with research focusing on their mechanisms of action and efficacy in neurological conditions.
Declining or Waning
- Traditional Herbal Medicine:
The interest in traditional herbal remedies as standalone treatments has diminished, possibly due to an increasing focus on evidence-based pharmacological approaches and the need for standardized treatment protocols. - Basic Animal Models:
The reliance on basic animal models for studying neurological diseases appears to be waning, as there is a growing emphasis on more sophisticated models that better replicate human conditions and disease mechanisms. - Single Agent Studies:
Research focusing solely on the efficacy of single-agent therapies is declining, with a shift towards combination therapies that address the multifactorial nature of neurological disorders. - Epidemiological Studies:
There seems to be a reduction in the publication of purely epidemiological studies, as the journal increasingly prioritizes studies that integrate clinical findings with molecular and pharmacological research.
Similar Journals
CELLULAR AND MOLECULAR NEUROBIOLOGY
Advancing the Frontiers of Neurobiology.CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.
Journal of Neuroimmune Pharmacology
Unveiling the Pharmacological Impact on Immune FunctionThe Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.
DRUG DEVELOPMENT RESEARCH
Exploring the frontiers of drug discovery and development.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.
Neurotherapeutics
Exploring New Horizons in Neurological Therapeutics.Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Exploring the Molecular Foundations of Biological Phenomena.ACTA BIOCHIMICA ET BIOPHYSICA SINICA, an esteemed journal published by SCIENCE PRESS, is a leading platform in the fields of biochemistry, biophysics, and molecular biology. Based in the United Kingdom, this journal has consistently ranked in the Q2 category for Biochemistry, Biophysics, and Medicine (miscellaneous) in 2023, showcasing its commitment to high-quality research and innovation in life sciences. With a convergence period extending from 1996 to 2024, it features critical insights into biochemical and biophysical processes that underlie biological phenomena. Researchers and professionals seeking to stay at the forefront of discoveries will find its articles to be both informative and transformative. Although not an open-access journal, ACTA BIOCHIMICA ET BIOPHYSICA SINICA aims to advance knowledge and foster collaboration among scientists worldwide, emphasizing its role in the dynamic landscape of biomedical research.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Innovating Therapeutic Strategies for a Healthier TomorrowThe JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.
ACS Chemical Neuroscience
Exploring the Chemistry of the Mind.ACS Chemical Neuroscience, published by the American Chemical Society, is a premier journal dedicated to exploring the complex interactions between chemistry and neuroscience. With its ISSN 1948-7193 and a distinguished impact factor that positions it within the top quartiles across multiple categories, including Q1 in Biochemistry, Q2 in Cell Biology, and Q1 in Physiology, this journal serves as an essential platform for researchers engaged in cutting-edge studies from 2010 to 2024. Positioned within the top 15% of its field in Cognitive Neuroscience according to Scopus rankings, ACS Chemical Neuroscience strives to foster interdisciplinary collaboration, publishing significant advancements that integrate chemical concepts with neurological processes. Despite its traditional publication model, the journal is committed to maintaining rigorous peer-review standards and providing valuable insights that drive innovations in therapeutics and understanding the biochemical underpinnings of brain function. Researchers, professionals, and students alike will find in this journal a vital resource for the latest findings and methodologies in the dynamic intersection of chemistry and neuroscience.
ACTA NEUROPATHOLOGICA
Transforming Understanding of Neurological DisordersACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.
International Journal of Molecular and Cellular Medicine
Empowering Research in Molecular Medicine and BeyondInternational Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.
Current Molecular Pharmacology
Empowering Scholars with the Latest in Drug DevelopmentCurrent Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.